Review the Benzocaine / Lidocaine / Tetracaine source preparation, its listed specifications and the details your practice should confirm with the pharmacy.
For product identification and informed clinic review. No patient checkout is provided.
Optimal names Benzocaine / Lidocaine / Tetracaine with 20% / 10% / 10% and a 60 mL package. Confirm ingredient assignment, exact forms, percentage basis, dosage form, route and full product documentation.
Listed package: 60 mL. Confirm the complete formulation, ingredient identities, percentage basis, dosage form, labeling and current pharmacy requirements. Source specifications are not application or dosing instructions.
Explore source listing1 source entry. Open the pharmacy to review its listings and confirmation notes.
| Source preparation / review note | Listed amount / specification | Package |
|---|---|---|
| Benzocaine/Lidocaine/Tetracaine 20%/10%/10%Confirm the finished dosage form, percentage basis and preparation-specific safety information. No procedure protocol is established. | 20% / 10% / 10% — source sequence | 60 mL |
Review the exact product with the responsible pharmacy before submitting an order.
Check the ingredient name and its complete specification.
Review product-specific evidence and regulatory information.
Confirm missing or conflicting fields with the pharmacy.
Any further action depends on the exact product and applicable requirements.
CoreLink does not prescribe or dispense. Reference listings are not offers to supply products.
The treating clinician determines suitability and prescribing. Review the exact preparation’s labeling and pharmacy information.
The initials BLT may describe the ingredient names but do not establish a standardized preparation. Source percentages are not an application amount, exposure limit or a validated procedure protocol.
FDA’s summary of the NASEM assessment describes limited evidence and important safety-data gaps for compounded topical pain creams. That general review does not validate this specific three-ingredient preparation or establish its dosage form. Obtain preparation-specific safety information. FDA: NASEM compounded topical pain cream assessment
Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness or quality. FDA: compounded drug information
Sources checked October 19, 2026. This page provides product information, not diagnosis, treatment selection, dosing or administration instructions.
No. The source lists ingredient names, percentages and a package volume. Confirm dosage form, vehicle, intended route and labeling. No application amount, exposure time or procedure instructions are provided.
No. A source entry does not establish approval, safety, effectiveness, current availability or eligibility. Review the exact preparation and current requirements with the responsible pharmacy.
No. Ingredient concentration, total content and package volume are separate specifications. This page gives no dosing, preparation or administration instructions.
No. Verify the exact product and its regulatory status. A compounded preparation is not FDA-approved, and a reference to an approved product does not establish equivalence.
A shared ingredient name or numerical value does not establish equivalence. Confirm the complete ingredient form, formulation, route and product labeling.
Ask for the exact ingredient identity, full formulation, strength units, dosage form, route, package, current labeling and applicable requirements. Resolve missing or conflicting information.
No. These pages provide reference information and no patient checkout. Patients should discuss treatment with their treating clinician.
Email info@corelinkpharm.com for platform questions. Contact the responsible pharmacy for preparation-specific information.
Contact CoreLink for account information. Ask the pharmacy about exact product specifications and eligibility.